StreetInsider.com News Articles

Form 4 PFIZER INC For: Jun 09 Filed by: DAMICO JENNIFER B.

Wed, 10 Jun 2026 19:58:00 -0400

si-local-file:///var/storage/secattach/20260610/26631245.html

Form 4 PFIZER INC For: Jun 09 Filed by: DAMICO JENNIFER B.

Wed, 10 Jun 2026 19:58:00 -0400

si-local-file:///var/storage/secattach/20260610/26631245.html

Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts

Wed, 10 Jun 2026 15:50:06 -0400

Investing.com -- Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while maintaining its $25 price target. The brokerage said the stock's roughly 11% pullback from its 2026 highs has brought valuation in line with its expectations, reducing the downside risks it had previously highlighted.

RBC said Pfizer's strong first-quarter results could support a higher 2026 outlook, while its dividend yield of nearly 7% should help underpin the shares. The firm believes concerns around revenue erosion and the company's lagging

Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts

Wed, 10 Jun 2026 15:50:06 -0400

RBC Capital Upgrades Pfizer (PFE) to Sector Perform

Wed, 10 Jun 2026 02:29:54 -0400

RBC Capital analyst Trung Huynh upgraded Pfizer (NYSE: PFE) from Underperform to Sector Perform with a price target of $25.00.

The analyst comments: “We upgrade PFE to Sector Perform from Underperform. Our overall thesis has not changed substantially, but the stock is down -11% from highs this year and is now trading in line with our 9x - 1Y fwd PE valuation. We think the risk reward is now more balanced going into two key catalysts: sigvotatug vedotin in 2L lung mid-26, and mevro 2H26. Additionally, strong 1Q26 fundamentals support a potential 2026 guidance upgrade, while the 7% dividend yield should

RBC Capital Upgrades Pfizer (PFE) to Sector Perform

Wed, 10 Jun 2026 02:29:54 -0400

RBC Capital analyst Trung Huynh upgraded Pfizer (NYSE: PFE) from Underperform to Sector Perform with a price target of $25.00.

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade.

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates

Tue, 09 Jun 2026 09:44:01 -0400

One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research and billions

FDA approves expanded HYMPAVZI use for hemophilia patients with inhibitors

Mon, 08 Jun 2026 06:45:20 -0400

Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration approved an expanded indication for HYMPAVZI to include patients with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients ages 6 to 11 years with or without inhibitors.

HYMPAVZI is now indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or hemophilia B, with or without inhibitors. The treatment is administered subcutaneously once weekly.